Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy
Authors:
- 14 August 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 26 (5) , 728-733
Abstract
Background: Patients with inflammatory bowel disease (IBD) may be at higher risk for complications from radiation treatment for prostate cancer. However, available data are limited, and controversy remains regarding the best treatment approach for IBD patients who develop prostate cancer. Methods: A retrospective cohort study across 4 Department of Veterans Affairs hospital systems. Patients with established IBD who were diagnosed and treated for prostate cancer between 1996–2015 were included. We assessed for flares of IBD, IBD-related hospitalizations, and IBD-related surgeries within 6, 12, and 24 months of cancer diagnosis and survival at 1, 2, and 5 years. Flares of IBD were those documented as such by the treating physician, and treatment changed accordingly. Results: One hundred patients with IBD and prostate cancer were identified. Forty-seven were treated with either treatment with external beam radiation or brachytherapy, and 53 were treated with nonradiation modalities. Comparing cohorts with or without radiation treatment, there were no differences in baseline IBD characteristics, Charlson comorbidity index, or prostate cancer stage. Inflammatory bowel disease flares were 2-fold higher for radiation-treated patients within 6 months (10.6% vs 5.7%) and 6–12 months (4.3% vs 1.9%) after cancer diagnosis. On multiple logistic regression analysis, radiation treatment (adjusted odds ratio, 4.82; 95% confidence interval, 1.15–20.26) was a significant predictor of flares. However, rates of IBD-related hospitalizations or surgeries were not significantly different. Conclusions: In this retrospective, multicenter study, 2-fold higher rates of flare were found within the first year after prostate cancer diagnosis for patients treated with radiation, but there were no differences in IBD-related hospitalizations or surgeries. Although patients should be counseled of these risks, avoidance of radiation therapy in IBD patients with prostate cancer is likely not necessary.Keywords
Funding Information
- AbbVie
- Janssen
- American Regent
- Eli-Lilly
- Genetech
- Celgene
- Pfizer
- Gilead
- Boehringer-Ingelheim
- Genentech
This publication has 16 references indexed in Scilit:
- Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel DiseaseReports of Practical Oncology and Radiotherapy, 2017
- Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerNew England Journal of Medicine, 2016
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerNew England Journal of Medicine, 2016
- Intensity‐modulated radiotherapy reduces toxicity with similar biochemical control compared with 3‐dimensional conformal radiotherapy for prostate cancer: A randomized clinical trialCancer, 2016
- Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation TherapyAmerican Journal of Clinical Oncology, 2015
- Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 TrialEuropean Urology, 2014
- Toxicity after 125I prostate brachytherapy in patients with inflammatory bowel diseaseBrachytherapy, 2013
- Patient and Treatment Factors Associated With Complications After Prostate BrachytherapyJournal of Clinical Oncology, 2006
- Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasmsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Prostate Brachytherapy in Patients with Inflammatory Bowel DiseaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998